| Abstract:
Background: Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic myelogenous leukemia (CML) and c-kit in patients with gastrointestinal stromal tumors (GISTs). Skin hypopigmentation is reported during Imatinib therapy. We present a case of CML who developed skin hyperpigmentation in the face during treatment with Imatinib which found chloasma-like appearance.
|